Puma Biotechnology, Inc. (PBYI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.55+1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Achieve revenue near $225.5M in fiscal 2026: FY26 rev guide $205M-$209M vs $225.5M target; trip < $195M.
Puma Biotechnology raised its 2026 revenue guidance to $225.5M. Cash from operations improved to $15.4M in 2026-Q1. The company aims for positive net income of about $11.5M in 2026. Profit margins remain stable near 23%.
Revenue growth is weak with a 2026-Q1 decline to $44.8M from $75.5M in 2025-Q4. The company reported a net loss of $3.75M in 2026-Q1. Analysts expect about -2% revenue growth next year. Risks remain elevated.
The price sits about 23% below our fair value near $10. Analysts expect about -2% revenue growth. Our view aligns with cautious growth but sees upside if guidance is met.
Breaks if: Cash from operations falls below $10M in next 4 quarters
Management focuses on maintaining strong cash flow from operations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
PBYI is a stable company with a strong recent financial performance. It operates in the healthcare sector, which currently has a favorable backdrop. The thesis is intact but carries some near-term risks.
The market appears to have a neutral valuation for PBYI, with expectations slightly below peers. There is a low level of fragility, indicating that the current setup is not overly sensitive to negative news.
Management has shown robust earnings quality and is on track to increase revenue guidance for 2026. However, there are mixed results regarding achieving positive net income and maintaining cash from operating activities.
The long-term thesis hinges on management's ability to meet revenue and income targets while navigating potential sector volatility. Key factors include the performance of sector bellwethers and overall economic conditions.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Gross margin falls below 20%
Management focuses on maintaining strong cash flow from operations.
Breaks if: Net income remains negative or below $10M in FY26
Breaks if: Revenue falls below $195M in FY26
Raise full year 2026 revenue guidance based on increased demand for NERLYNX and commercial execution.
Stated as a priority in 3 of last 3 quarters. Management raised full year 2026 revenue guidance from $214–$221 million (2026-Q1) to $224–$231 million (2026-Q2). Second quarter 2026 revenue grew to $56.5 million from $52.4 million in 2025-Q2. The trajectory shows delivering growth consistent with management's stated priority.
“Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX”
“We are raising revenue guidance for 2026.”
“Full Year 2026... Total Revenue $214–$221 million”
In the next 1 to 3 years, PBYI's performance will depend on management execution and external market conditions. Not investment advice.